Association of ST2 levels with cardiac structure and function and mortality in outpatients

Daniels, Lori B.; Clopton, Paul; Iqbal, Navaid; Tran, Kimberly D.; Maisel, Alan S.

doi:10.1016/j.ahj.2010.06.033

Cited by 98 publications

(57 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A central role of IL‐33 has been identified in cardiomyocytes protecting against progressive fibrosis and hypertrophy 10. Studies in patients with shortness of breath,11, 12, 13, 14 chest pain,15 and those referred for outpatient echocardiograms16 have shown poorer prognosis among those with higher concentrations of circulating sST2, irrespective of the final clinical diagnosis. Among population‐based studies, the Dallas Heart Study reported increased all‐cause and cardiovascular mortality in younger and middle‐aged adults with greater circulating sST2,17 and there was an increased risk of HF, death, and major cardiovascular events among middle‐aged adults with greater sST2 in the Framingham Heart Study (FHS) 18…”

Section: Introductionmentioning

confidence: 99%

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Parikh

Seliger

Christenson

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundSoluble ST2 (sST2), a marker of myocyte stretch and fibrosis, has prognostic value in many cardiovascular diseases. We hypothesized that sST2 levels are associated with incident heart failure (HF), including subtypes of preserved (HFpEF) and reduced (HFrEF) ejection fraction, and cardiovascular death.Methods and ResultsBaseline serum sST2 was measured in 3915 older, community‐dwelling subjects from the Cardiovascular Health Study without prevalent HF. sST2 levels were associated with older age, male sex, black race, traditional cardiovascular risk factors, other biomarkers of inflammation, cardiac stretch, myocardial injury, and fibrosis, and abnormal echocardiographic parameters. In longitudinal analysis, greater sST2 was associated with a higher risk of incident HF and cardiovascular death; however, in multivariate models adjusting for other cardiac risk factors and the cardiac‐specific biomarker, N‐terminal pro–type B natriuretic peptide, these associations were attenuated. In these models, an sST2 level above the US Food and Drug Administration–approved cut‐off value (>35 ng/mL) was significantly associated with incident HF (hazard ratio [HR], 1.20; 95% CI, 1.02–1.43) and cardiovascular death (HR, 1.21; 95% CI, 1.02–1.44), and greater sST2 was continuously associated with cardiovascular death (per 1‐ln increment: HR, 1.24; 95% CI, 1.02–1.50). sST2 was not associated with the HF subtypes of HFpEF and HFrEF in adjusted analysis. Addition of sST2 to existing risk models of HF and cardiovascular death modestly improved discrimination and reclassification into a higher risk.ConclusionsThe predictive value of sST2 for HF of all subtypes and cardiovascular death is modest in an elderly population despite strong cross‐sectional associations with risk factors and underlying cardiac pathology.

show abstract

Section: Introductionmentioning

confidence: 99%

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Parikh

Seliger

Christenson

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…139 The role appears to be predominantly prognostic, 140 but a role in the emergency department population has been questioned, 141 as has the concept of additional risk prediction over current markers. 142 The major role appears to be as a marker of myocardial remodelling [143][144][145] and hence dysfunction. In patients with acute heart failure, elevation of ST2 predicts an adverse outcome and is an independent prognostic marker.…”

mentioning

confidence: 99%

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

Collinson

Gaze²,

Thokala³

et al. 2013

Health Technol Assess

View full text Add to dashboard Cite

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.hta.ac.uk/ This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 09/22/16. The contractual start date was in August 2010. The draft report began editorial review in February 2012 and was accepted for publication in June 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by the NIHR Journals Library, produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk). Objectives: To test the diagnostic accuracy for detecting an acute myocardial infarction (AMI) using highly sensitive troponin assays and a range of new cardiac biomarkers of plaque destabilisation, myocardial ischaemia and necrosis; to test the prognostic accuracy for detecting adverse cardiac events using highly sensitive troponin assays and this range of new cardiac biomarkers; and to estimate the cost-effectiveness of using highly sensitive troponin assays or this range of new cardiac biomarkers instead of an admission and 10-to 12-hour troponin measurement. NIHR Journals LibraryDesign: Substudy of the point-of-care arm of the RATPAC (Randomised Assessment ...

show abstract

“…Он имеет 4 изоформы, являю-щиеся транскрипционными продуктами гена, 2 из которых напрямую вовлечены в развитие ССЗ: рас-творимая форма (sST2) и мембран-связанная фор-ма рецептора (ST2L) [8]. Цитокин интерлейкин-33 (IL-33) является функциональным лигандом ST2L [9][10][11], он связывается с ST2L на клеточной мемб-ране в процессах воспаления [12][13][14].…”

Section: структура и функция St2unclassified

St2 in Rejection of the Transplanted Heart

Шевченко

Улыбышева

Velikiy

et al. 2016

RJTAO

View full text Add to dashboard Cite

1 ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России, Москва, Российская Федерация 2 ГБОУ ВПО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России, Москва, Российская Федерация 3 ГБОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России, кафедра кардиологии, Москва, Российская Федерация Обзор литературы посвящен анализу прогностической роли биомаркера ST2 при отторжении транс-плантированного сердца. ST2 является одним из наиболее перспективных диагностических маркеров развития и тяжести течения сердечной недостаточности, а также риска смерти у больных сердечно-со-судистыми заболеваниями. ST2 экспрессируется в кардиомиоцитах в ответ на патологические процессы и различные механические повреждения в сердце, что позволяет диагностировать сердечно-сосудистые заболевания еще до клинических проявлений. Предположительно измерение уровня ST2 при трансплан-тации сердца может иметь диагностическое и прогностическое значение при оценке состояния транс-плантата и риска развития отторжения. В настоящее время клинических данных о роли биомаркера при трансплантации сердца накоплено недостаточно, и необходимы дальнейшие исследования связи уровня ST2 с различными клиническими и лабораторными показателями у реципиентов сердца. This review summarizes the current literature devoted to the analysis of prognostic role of ST2 biomarker in rejection of the transplanted heart. ST2 is one of the most promising diagnostic markers of the development and severity of heart failure as well as the mortality risk in patients with cardiovascular diseases. ST2 is expressed in cardiomyocytes in response to a variety of pathological processes and mechanical damage to the heart, which allows diagnosing cardiovascular diseases before clinical manifestations. Presumably, measuring the level of ST2 in heart transplant may have diagnostic and prognostic value in the assessment of graft and risk of rejection. Currently, accumulated clinical data on the role of given biomarker in heart transplantation are not enough, and further research on the relation of ST2 levels with different clinical and laboratory parameters in heart recipients is necessary.Key words: heart transplantation, ST2, heart failure, rejection. Сердечно-сосудистые заболевания (ССЗ) явля-ются основной причиной смертности во всем мире, при этом, несмотря на развитие медикаментозной терапии и хирургических методов, с каждым го-дом этот показатель только увеличивается. Акту-альным вопросом является поиск новых методик, маркеров, позволяющих обнаружить ССЗ еще на ранних этапах развития, когда их лечение наиболее эффективно. На сегодняшний день одним из наибо-лее перспективных биомаркеров сердечной недо-статочности (СН) является ST2 [1]. Этот новейший маркер, используемый в первую очередь для про-гнозирования риска сердечной недостаточности, во многом информативнее таких маркеров ССЗ, как BNP и NT-proBNP. Наряду с этим биомарке...

show abstract

Association of ST2 levels with cardiac structure and function and mortality in outpatients

Cited by 98 publications

References 31 publications

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community‐Dwelling Population

Randomised Assessment of Treatment using Panel Assay of Cardiac markers – Contemporary Biomarker Evaluation (RATPAC CBE)

St2 in Rejection of the Transplanted Heart

Contact Info

Product

Resources

About